{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T12:09:16Z","timestamp":1777032556016,"version":"3.51.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1097\/01.wnf.0000169732.00690.32","type":"journal-article","created":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T18:54:38Z","timestamp":1122922478000},"page":"188-190","source":"Crossref","is-referenced-by-count":21,"title":["Levetiracetam-Induced Parkinsonism in a Huntington Disease Patient"],"prefix":"10.1097","volume":"28","author":[{"given":"Theresa A","family":"Zesiewicz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Sanchez-Ramos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly L","family":"Sullivan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210203","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntingtons disease chromosomes.","volume":"72","year":"1993","journal-title":"Cell"},{"key":"R2-8-20210203","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1176\/ajp.140.6.728","article-title":"Psychiatric syndromes in Huntingtons disease.","volume":"140","author":"Caine","year":"1983","journal-title":"Am J Psychiatry"},{"key":"R4-8-20210203","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1212\/WNL.38.1.84","article-title":"Serum haloperidol concentration and choreiform movements in Huntingtons disease.","volume":"38","author":"Barr","year":"1988","journal-title":"Neurology"},{"key":"R5-8-20210203","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/00004850-200403000-00001","article-title":"Huntingtons disease: present treatments and future therapeutic modalities.","volume":"19","author":"Bonelli","year":"2004","journal-title":"Int Clin Psychopharmacol"},{"key":"R6-8-20210203","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial.","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"R7-8-20210203","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multi-center double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group.","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"R8-8-20210203","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-2999(00)00105-9","article-title":"Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonia activity in a hamster model of paroxysmal dystonia.","volume":"391","author":"Loscher","year":"2000","journal-title":"Eur J Pharmacol"},{"key":"R9-8-20210203","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/mds.10542","article-title":"Novel antiepileptic drug levetiracetam decreases dyskinesia elicited by L-dopa and ropinirole in the MPTP-lesioned marmoset.","volume":"18","author":"Hill","year":"2003","journal-title":"Mov Disord"},{"key":"R10-8-20210203","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejphar.2003.11.065","article-title":"Levetiracetam improves choreic levodopa-induced dyskinesia in the MPTP-treated macaque.","volume":"485","author":"Bezard","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"R11-8-20210203","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/mds.10118","article-title":"Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis.","volume":"17","author":"Chatterjee","year":"2002","journal-title":"Mov Disord"},{"key":"R12-8-20210203","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1002\/mds.20233","article-title":"Substantial improvement in a Meiges syndrome patient with levetiracetam treatment.","volume":"19","author":"Zesiewicz","year":"2004","journal-title":"Mov Disord"},{"key":"R14-8-20210203","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.yebeh.2003.09.007","article-title":"Use of levetiracetam in a population of patients aged 65 years and older: a subset analysis of the KEEPER trial.","volume":"4","author":"Ferrendelli","year":"2003","journal-title":"Epilepsy Behav"},{"key":"R15-8-20210203","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician.","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatry Res"},{"key":"R18-8-20210203","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R19-8-20210203","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1083\/jcb.100.4.1284","article-title":"Identification of a transmembrane glycoprotein specific for secretory vesicles of neural and endocrine cells.","volume":"100","author":"Buckley","year":"1985","journal-title":"J Cell Biol"},{"key":"R20-8-20210203","doi-asserted-by":"crossref","first-page":"5223","DOI":"10.1523\/JNEUROSCI.14-09-05223.1994","article-title":"Differential expression of synaptic vesicle protein 2 (SV2) isoforms.","volume":"14","author":"Bajjalieh","year":"1994","journal-title":"J Neurosci"},{"key":"R21-8-20210203","first-page":"498","article-title":"Facilitation of calcium-dependent cholinergic function by UCB L059, a new second generation nootropic agent.","volume":"25","author":"Wulfert","year":"1989","journal-title":"Psychopharmacol Bull"},{"key":"R22-8-20210203","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2169\/internalmedicine.39.863","article-title":"Parkinsonism onset in a patient concurrently using tiapride and donepezil.","volume":"39","author":"Arai","year":"2000","journal-title":"Intern Med"},{"key":"R23-8-20210203","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1345\/aph.17355","article-title":"Possible association between donepezil and worsening Parkinsons disease.","volume":"32","author":"Bourke","year":"1998","journal-title":"Ann Pharmacother"},{"key":"R24-8-20210203","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gps.993","article-title":"Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinsons disease.","volume":"19","author":"Leroi","year":"2004","journal-title":"Int J Geriatr Psychiatry"},{"key":"R25-8-20210203","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.pnpbp.2003.09.008","article-title":"Muscarinic mechanisms of antipsychotic atypicality.","volume":"27","author":"Bymaster","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.wnf.0000169732.00690.32","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T21:44:11Z","timestamp":1620942251000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200507000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.wnf.0000169732.00690.32","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}